The objective is to observe if it could be possible to use the apoptosis test to distinguish different aetiologies in chronic pelvic pain syndrome (CPPS). A prospective study was done, 106 patients, 57 had previously been diagnosed with urological chronic pelvic pain (UCPP)/interstitial cystitis (IC) and 49 patients with gynaecological chronic pelvic pain (GCPP). Neoplastic cells cultures were exposed to the urine of patients with UCPP/IC and patients with GCPP. The urine ability to provoque apoptosis on them was analysed. The apoptosis degree was measured by quantifying the percentage of cells in phase subG0, determined by a flow cytometry analysis. It is observed that the cell cultures exposed to urine of patients with UCPP had a significantly higher sub-G1 peak and G2 phase than those of the cells exposed to urine from patient’s GCPP. The average values of apoptosis in patients with UCPP were significantly higher to that obtained in -patients having GCPP. With the apoptosis tests having a value >10%, it is considered as positive as well. This means that when we are faced with a patient who has UCPP or non-bladder chronic pelvic pain, the probability of having an UCPP increases by 45% when the apoptosis test is positive for a value >10%. Urine from patients with UCPP has significantly higher apoptotic effect over than the effect produced by urine from patients with GCPP. The apoptosis test could be useful as an illness biomarker.

1.
Engeler D, Baranowski AP, Borovicka J, Cottrell A, Dinis-Oliveira P, Elneil S, et al. Guidelines on Chronic Pelvic Pain. EUA guidelines. 2015;14.
2.
Abrams P, Baranowski A, Berger RE, Fall M, Hanno P, Wesselmann U. A new classification is needed for pelvic pain syndromes–are existing terminologies of spurious diagnostic authority bad for patients?
J Urol
. 2006 Jun;175(6):1989–90.
3.
Nader A, Candido KD; AN. Pelvic pain.
Pain Pract
. 2001 Jun;1(2):187–96.
4.
Rapariz-González M, Castro-Díaz D, Mejía-Rendón D; EURCIS. Evaluation of the impact of the urinary symptoms on quality of life of patients with painful bladder syndrome/chronic pelvic pain and radiation cystitis: EURCIS study.
Actas Urol Esp
. 2014 May;38:224–31.
5.
Di Capua-Sacoto C, Sanchez-Llopis A, O’Connor E, Martinez A, Ruiz-Cerdá JL; Di CapuaSacoto C. Study of the apoptotic effect of urine as a diagnostic biomarker in patients with interstitial cystitis.
Actas Urol Esp
. 2016 Nov;40(9):570–6.
6.
Moore J, Kennedy S. Causes of chronic pelvic pain.
Baillieres Best Pract Res Clin Obstet Gynaecol.
2000 Jun;14(3):398–402.
7.
Itza F, Zarza D, Gómez-Sancha F, Salinas J, Bautrant E. Puesta al día en el diagnóstico y tratamiento de la vulvodinia.
Actas Urol Esp
. 2012 Jul-Aug;36(7):431–8.
8.
Augé L, AnteloJL, BuquetR, Dionisi H, Etchepareborda JJ, Martinez A, et al. Consenso de endometriosis Septiembre 2012.
Fasgo
. 2013;11(2):49–62.
9.
Itza Santos F, Salinas J, Zarza D, Gómez Sancha F, Allona Almagro A. Actualización del síndrome de atrapamiento del nervio pudendo: enfoque anatómico-quirúrgico, diagnóstico y terapéutico.
Actas Urol Esp
. 2010 Jun;34(6):500–9.
10.
Clemens JQ, Calhoun EA, Litwin MS, ­McNaughton-Collins M, Kusek JW, Crowley EM, Landis JR; Urologic Pelvic Pain Collaborative Research Network. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women.
Urology
. 2009 Nov;74:983–7, quiz 987.e1–3.
11.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al.; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.
Neurourol Urodyn
. 2002;21(2):167–78.
12.
Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, et al. Members of the European Association of Urology (EAU). Guidelines Office. Guidelineson Chronic Pelvic Pain. In: EAU Guidelines. Edition presented at the 25th EAU Annual Congress. Barcelona; 2010.
13.
Keay S, Zhang CO, Trifillis AL, Hise MK, Hebel JR, Jacobs SC, et al. Decreased 3H-thymidine incorporation by human bladder epithelial cells following exposure to urine from interstitial cystitis patients.
J Urol
. 1996 Dec;156(6):2073–8.
14.
Erickson DR, Ordille SD, Zhang CO. Antiproliferative factor (APF), heparin binding epidermal growth factor-factor-like growth factor (HB- EGF) and epidermal growth factor (EGF) alterations in interstitial cystitis (IC) confirmed.
J Urol
. 2000;163:62.
15.
Erickson DR, Xie SX, Bhavanandan VP, Wheeler MA, Hurst RE, Demers LM, et al. A comparison of multiple urine markers for interstitial cystitis.
J Urol
. 2002 Jun;167(6):2461–9.
16.
u Zhang CO, Li ZL, Shoenfelt JL, Kong CZ, Chai TC, Erickson DR, et al. Comparison of APF activity and epithelial growth factor levels in urine from Chinese, African-American, and white American patients with interstitial cystitis.
Urology
. 2003 May;61(5):897–901.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.